ASH Annual Meeting

The use of iberdomide alone or with anti-CD20 antibodies show efficacy in patients with relapsed or refractory lymphoma.

Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.

Positive results were shown with ziftomenib monotherapy in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

MAGNOLIA study results demonstrated that zanubrutinib maintained response in patients with relapsed/refractory marginal zone lymphoma.

Phase 1/2 BRUIN study results show high response rates in patients with Waldenström macroglobulinemia who were treated with pirtobrutinib.

Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Olverembatinib is efficacious and well tolerated in tyrosine kinase inhibitor-resistant CML-CP and CML-AP patients with a BCR-ABL1 T315I mutation.

Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.

Salvage chemotherapy after lintuzumab-Ac225 showed promising early efficacy results in patients with relapsed/refractory acute myeloid leukemia by eliminating residual leukemia cells.

Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Liso-cel was found to improve quality of life in patients with large B-cell lymphoma compared with standard of care.

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.

Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.

Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.

Magrolimab will be tested in combination with various antileukemia therapies at multiple disease points, such as the first line and remission stages.

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

Venetoclax dosed at either 400 mg or 800 mg in combination with daratumumab and dexamethasone showed promising preliminary results in a phase 1/2 study.

In the MEDALIST analysis that was presented at the 2021 ASH Annual Meeting, investigators sought to further characterize the effects of luspatercept in patients with low-risk myelodysplastic syndrome.

Having knowledge that their multiple myeloma was incurable was associated with poor quality of life outcomes in patients.

The XVd regimen appears effective at prolonging progression-free survival with decreased toxicity when administered at lower doses of selinexor or the standard dose.

Polatuzumab vedotin-piiq added to the R-CHOP regimen elicited a high progession-free survival rate in patients with newly-diagnosed diffuse large B-cell lymphoma.

Updated results from CARTITUDE-1 reveal deep and durable response to ciltacabtagene autoleucel treatment in patients with multiple myeloma.

Preliminary results from the phase 2 ERADIC trial signal promise for ibrutinib plus venetoclax for the treatment of chronic lymphocytic leukemia.

An early and deep response was seen with a single infusion of cilta-cel in patients with multiple myeloma who experienced early clinical relapse.

A more durable and deep responses was produced with the recommended phase 2 dose of selinexor plus pomalidomide and dexamethasone compared with the lesser selinexor dose for relapsed or refractory multiple myeloma.

While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.

In patients with relapsed/refractory multiple myeloma with t(11;14), Selinexor plus venetoclax induced decreases in cyclin D1, XPO1, and MCL-1.

Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.

Durable responses and tolerability for patients was seen with itolizumab for acute graft-versus-host disease.